GHRP-6 10mg

What Is GHRP-6?

GHRP-6, a powerful catalyst for the release of Growth Hormone from the anterior pituitary gland, also operates as an agonist for the ghrelin/growth hormone receptor. It is recognized under a class of recently developed ghrelin analogues. The peptide has exhibited multifaceted benefits, encompassing heart muscle cells, sex drive, scar healing, memory formation and neurons linked to Parkinson’s disease. When administered orally or sublingually, GHRP-6 remains active while exhibiting moderate to high selectivity for its target receptors.

GHRP-6 Structure

Source: PubChem

• Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys
• Molecular Formula: C₄₆H₅₆N₁₂O₆
• Molecular Weight: 873.032 g/mol
• PubChem CID: 9919153
• CAS Number: 87616-84-0

GHRP-6 Effects

1. Improves Memory

The exact mechanism of memory formation and learning has proven elusive, but scientists believe that engaging in physical activity after learning something new can improve cognition. There is ongoing research regarding the potential relationship between physical activity and the enhancement of learning and memory formation.

Previous research linked positive effects of physical activity to increased blood flow and mentions of growth hormone (GH), without offering a comprehensive analysis as to why. Trials conducted in animal models, specifically rats, suggest a possible explanation of GH’s impact on memory formation. Namely, aside from affecting the release of Growth Hormone, GHRP-6 consolidates recently formed memories and transforms short-term memories into long-term storage.

According to results of hitherto conducted research, ghrelin/GHRP-6 has an impact on tasks related to spatial learning, implying that the cognitive benefits resulting from physical activity could be facilitated by growth hormone secretagogues such as ghrelin. Furthermore, there is evidence backing the notion that GH acts indirectly, and likely secondary to the actions of the aforementioned peptides.

2. Protects Brain Tissue

Researchers are exploring animal models of stroke to better understand GHRP-6’s efficacy in protecting neurons and other cells in the central nervous system from the adverse effects of insufficient blood supply. Given it’s administered promptly after a stroke, GHRP-6 has demonstrated the ability to alleviate memory deficits, aside from providing protection to brain tissue. Apoptosis, programmed cell death, is effectively inhibited by ghrelin and its analogues, with the addition of reduced inflammation in the brain as another effect they demonstrate. Combined, these actions form a mechanism that shields neurons from post-stroke conditions and impacts of genetic programming.

Pathway by which ghrelin inhibits apoptosis and reduces inflammation
Source: PubMed

3. Protects Parkinson’s Neurons

Research investigation conducted in 2018 provided fresh insights into the protective capabilities of GHRP-6 for brain tissue, specifically regarding Parkinson’s disease. It was revealed that substantia nigra, part of the brain impacted by Parkinson’s, harbored ghrelin receptors. Those with genetic predispositions for Parkinson’s disease have demonstrated a lower number of ghrelin receptors on neurons in substantia nigra. Upon receiving an antagonist injection, rats with the same deficiency exhibit symptoms resembling Parkinson’s.   

Implicitly, agonists like GHRP-6 might offer potential benefits in treating Parkinson’s. It is hypothesized that through binding to the diminished receptors, these peptides could potentially reduce neuronal apoptosis in the substantia nigra – potentially slowing down or preventing the onset of Parkinson’s.

4. Improves Skin Appearance and Reduces Scaring

By decreasing programmed cell death, the peptide enhances survival across different cell types. GHRP-6 engages with the receptor recognized for its role in stimulating the growth of blood vessels and wound healing, known as CD36. Evidence in studies involving rats suggests the efficacy of these properties in wound healing. Expediting the closure of wounds, GHRP-6 also interrupts the process of scar formation and boosts the production of essential extracellular proteins such as collagen. Consequently, this contributes to reduced scar tissue formation and an improved overall wound structure.

The development of hypertrophic scars, caused by improper deposition of extracellular matrix proteins, can effectively be prevented by GHRP-6. The significance of this finding lies in reassuring people suffering from this abnormal healing process, regarding surgeries and medical procedures that could otherwise lead to aesthetic changes and painful scar formation.

5. Reduces Heart Problems

Research on pigs experiencing heart attack indicates that GHRP-6 shows promise in averting oxidant cytotoxicity, providing a protective barrier for heart cells against harm caused by free radicals. With this discovery rises the potential of creating drugs that could protect susceptible yet viable cells post-heart attack. The potential of such a drug lies in its ability to reduce mortality and improve overall outcomes after experiencing myocardial infarction.

6. Alters Sex Motivation and Mood

As observed in male rat models, elevated ghrelin levels potentially boost sexual drive, suggesting that ghrelin receptors in the central nervous system can influence sexual behavior. Findings in studies involving GHRP-6 and its modified version aimed at blocking ghrelin receptors imply that these receptors in specific brain regions contribute to the regulation of both reward-seeking and sexual behavior. Aside from sexual disorders such as HSDD (hypoactive sexual desire disorder), results of the studies potentially encompass various forms of motivation such as hunger.

Studies involving rat models support the idea that ghrelin could potentially impact mood as part of its effect on motivation. Namely, GHRP-6 and other agonists targeting ghrelin receptors have the potential to alleviate depression, as well as enhance the functioning of brain regions related to mood and stress. Consequently, GHRP-6 holds the potential of being the foundation for researching new treatments of various mood disorders such as depression, stress and anxiety.

GHRP-6 displays minimal to moderate side effects, low oral bioavailability, and exhibits excellent subcutaneous bioavailability in mice. It’s crucial to recognize that the dosage per kg administered to mice can’t be directly translated to humans. At the shop, the sale of GHRP-6 is restricted solely to educational and scientific research, explicitly excluding human consumption. Only researchers holding proper licenses are encouraged to purchase GHRP-6.

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Márta Korbonits graduated in Medicine in Budapest and undertook her early clinical training at the Internal Medicine Department of the Postgraduate Medical School, Budapest. She joined the Department of Endocrinology at St. Bartholomew’s Hospital under the mentorship of Professors Ashley Grossman and Michael Besser. Her MD and later PhD studies contributed to the understanding of the effects of growth hormone secretagogues on hypothalamic hormone release and the nature and causes of pituitary tumorigenesis. She was awarded an MRC Clinician Scientist Fellowship and commenced studies that produced novel insights into ghrelin physiology and genetics.

Her findings related to the regulation of the metabolic enzyme AMPK by ghrelin, cannabinoid and glucocorticoid opened a new aspect of hormonal regulation of metabolism. In 2008, Márta Korbonits was promoted to Professor of Endocrinology and Metabolism and since 2012, has led the Centre of Endocrinology at Barts and the London School of Medicine. In 2016, Márta Korbonits was appointed a Deputy Head of the William Harvey Research Institute. Professor Korbonits continues to integrate human studies alongside with laboratory-based research and has pioneered several projects in translational medicine.

Márta Korbonits is being referenced as one of the leading scientists involved in the research and development of GHRP-6. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Shop and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Márta Korbonits is listed in [12] under the referenced citations.

Resourced Citations

1. C.-C. Huang, D. Chou, C.-M. Yeh, and K.-S. Hsu, “Acute food deprivation enhances fear extinction but inhibits long-term depression in the lateral amygdala via ghrelin signaling,” Neuropharmacology, vol. 101, pp. 36–45, Feb. 2016.
2. S. Beheshti and S. Shahrokhi, “Blocking the ghrelin receptor type 1a in the rat brain impairs memory encoding,” Neuropeptides, vol. 52, pp. 97–102, Aug. 2015.
3. K. Tóth, K. László, and L. Lénárd, “Role of intraamygdaloid acylated-ghrelin in spatial learning,” Brain Res. Bull., vol. 81, no. 1, pp. 33–37, Jan. 2010.
4. N. Subirós et al., “Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy,” Neurol. Res., vol. 38, no. 3, pp. 187–195, Mar. 2016.
5. S. J. Spencer, A. A. Miller, and Z. B. Andrews, “The Role of Ghrelin in Neuroprotection after Ischemic Brain Injury,” Brain Sci., vol. 3, no. 1, pp. 344–359, Mar. 2013.
6. Y. Suda et al., “Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson’s disease-like motor dysfunction,” Mol. Brain, vol. 11, no. 1, p. 6, 20 2018.
7. Y. Mendoza Marí et al., “Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds,” Plastic Surgery International, 2016. [Online]. Available: https://www.hindawi.com/journals/psi/2016/4361702/. [Accessed: 23-May-2019].
8. M. Fernández-Mayola et al., “Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study,” Int. Wound J., vol. 15, no. 4, pp. 538–546, Aug. 2018.
9. J. Berlanga et al., “Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction,” Clin. Sci. Lond. Engl. 1979, vol. 112, no. 4, pp. 241–250, Feb. 2007.
10. L. Hyland et al., “Central ghrelin receptor stimulation modulates sex motivation in male rats in a site dependent manner,” Horm. Behav., vol. 97, pp. 56–66, 2018.
11. H.-J. Huang et al., “The protective effects of Ghrelin/GHSR on hippocampal neurogenesis in CUMS mice,” Neuropharmacology, May 2019.
12. Korbonits, Marta, and Ashley B. Grossman. “Growth Hormone-Releasing Peptide and Its Analogues.” Trends in Endocrinology & Metabolism, vol. 6, no. 2, Mar. 1995, pp. 43–49

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.